Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15304803 | 0.90 | LTA4H (0.42) | HTR1AHRH2HRH1HRH3 | |
| SCHEMBL6978837 | 0.80 | KCNA3 (0.36) | HRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL6978681 | 0.79 | PSMB1 (0.39) | — | |
| SCHEMBL13151498 | 0.78 | PSMB1 (0.41) | HRH3ALDH1A1 | |
| SCHEMBL9975277 | 0.78 | PSMB1 (0.41) | HRH3ALDH1A1 | |
| SCHEMBL6959283 | 0.77 | HTR1A (0.38) | HTR1AHRH2HRH1HRH3 | |
| Hydrochloric Acid SCHEMBL28035282 | 0.76 | PSMB1 (0.41) | HRH3ALDH1A1 | |
| SCHEMBL13656333 | 0.74 | HTR1A (0.47) | HTR1AHRH2HRH1HRH3ALDH1A1 | |
| SCHEMBL6980020 | 0.72 | GNAI3 (0.42) | HRH2HRH1HRH3 | |
| SCHEMBL20698407 | 0.72 | HTR1A (0.58) | HTR1AHRH2HRH1HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854789-B1 | QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | HTR1A 489/4885HRH2 138/4885HRH1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.